Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis by Leif Schiffmann et al.
Schiffmann et al. BMC Cancer 2013, 13:388
http://www.biomedcentral.com/1471-2407/13/388RESEARCH ARTICLE Open AccessPrognosis of rectal cancer patients improves with
downstaging by intensified neoadjuvant
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Background: Neoadjuvant radiochemotherapy has been proven superior to adjuvant treatment in reducing the
rate of local recurrence without impairing cancer related survival or the incidence of distant metastases in standard
protocols of neoadjuvant radiochemotherapy. The present study aimed at addressing the effects of an intensified
neoadjuvant radiochemotherapy on long term cancer related and disease free survival.
Methods: A total of 387 patients underwent oncologic resection for rectal cancer in our institution between
January 2000 and December 2009. There were 106 patients (27.4%) who received an intensified radiochemotherapy
protocol completely and without excluding criteria (study group). A matched pair analysis was performed by
comparing the study group with patients undergoing primary surgery and postoperative radiochemotherapy, if
necessary and possible (control group). Matching was carried out in descending order for UICC stage, R-status,
tumor height, T-, N-, V-, L-, M- and G-category of the TNM-system according to the histopathological staging.
Follow-up data included local recurrence rate, cancer related and disease free survival.
Results: In the study group histopathological work-up of the specimen revealed a treatment response in terms of
tumor regression in 92.5% (98/106) of these patients. Undergoing intensified neoadjuvant RCT the actuarial cancer
related and disease free survival was 67.9% and 70.4%, local recurrence was 5.7% after an observation period of 4.3 ±
2.55 years. In the control group cancer related and disease free survival was 71.7% and 82.7%, local recurrence was
4.7% after an observation period of 3.8 ± 3.05 years revealing no statistical significant difference between the two
groups. Moreover, estimated 5-year results of cancer related survival (66.7% vs 67.9% (controls)), the disease free
survival (66.7% vs 79.9% (controls)) as well as subgroup analysis of UICC 0-III and UICC IV patients showed no
difference between the study and control group as well.
Conclusion: In our study, intensified neoadjuvant radio-chemotherapy shows a high rate of tumor regression. The
resulting inferior histopathological tumor stage shows the same long term local control and systemic tumor
control as the control group with a primary more favorable tumor stage.
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For advanced rectal cancer, neoadjuvant radiochemother-
apy (RCT) has been proven to reduce the rate of local re-
currence in comparison to postoperative treatment [1] or
preoperative radiotherapy alone [2,3]. German guidelines
state exact treatment rules for UICC stage I to III and
localization of cancer in the rectum [4] depending on the
local tumor stage at initial tumor diagnosis. Since there is
no benefit of neoadjuvant radio-(chemo)therapy on cancer
related survival or distant metastases [1-3], efforts have
been made to improve the systemic results of these
protocols. By adding a second drug to the neoadjuvant
radiochemotherapy, the rate of complete responses and
tumor regression grade could be increased [5-7]. A
complete response has been shown to be a predictive
marker for disease free and cancer related survival.
Thus, an intensified neoadjuvant RCT protocol was in-
troduced at several institutions including irinotecan or
oxaliplatin [7-18] which uniformly confirmed improved
tumor response resulting in complete response rates up
to 23% and tumor/nodal downstaging in up to 65% [19].
However, long-term follow-up data such as overall or
disease free survival as well as local recurrences of any
of the intensified neoadjuvant radiochemotherapy pro-
tocols are still not available.
The aim of our study was therefore to investigate,
whether an intensified neoadjuvant radiochemother-
apy leads to an improvement of the respective onco-
logical long term end-points beyond downstaging and
tumor regression compared with patients receiving no
neoadjuvant treatment at all.
Patients and methods
A total of 387 patients with rectal cancer underwent on-
cologic resection in our institution between January
2000 and December 2009 and were included into this
retrospective matched pair analysis by screening the
pathological data base. The term rectum carcinoma was
applied to adenocarcinomas located at a distance from 0
to 16 cm from the anal verge measured by rectoscopy.
The cancer was located in either the lower (0- < 6 cm),
middle (6- < 12 cm) or upper (12-16 cm) rectum.
According to the current German guidelines, indication
for neoadjuvant RCT was given for T3, T4 and/or nodal
positive tumors of the lower and middle third of the rec-
tum. In the upper third of the rectum, the only indication
for neoadjuvant treatment was a T4 cancer.
Pretherapeutic studies included routine laboratory ana-
lysis, ECG, endoscopy and biopsy, abdomen ultrasound or
computertomography, endoluminal ultrasound for local
staging and chest radiography.
In our institution, patients usually received an intensi-
fied radiochemotherapy with some modification of the
chemotherapy drugs during the observation period. FromJanuary 2000 to January 2002 patients received a combin-
ation of a continuous infusion 5-FU (250 mg/m2 per day)
over 31 days, irinotecan (initially 6 times, once a week
with 40 mg/m2; later 4 times, once weekly in week 1, 2, 4,
and 5 with 60 mg/m2) and a local radiation five days a
week with a single dose of 1.8 Gy adding up to 50.4 Gy
(last three doses were reduced). From February 2002 5-FU
was replaced by a daily intake of Capecitabine with a
single dose between 1000 and 1650 mg/m2. Doses of radi-
ation were no longer reduced and reached a cumulative
dose of 55.4 Gy. Oxaliplatin had been applied instead of
Irinotecan in eight patients. Following surgery, patients
usually received adjuvant chemotherapy with 5-FU with
or without folinic acid or Capecitabine according to the
recommendations of the German Cancer Society (DKG).
Additionally, irinotecan or oxaliplatin was applied in 23
patients.
The type of surgery depended on localization of the
tumor, preoperative stool incontinence and general
condition of the patient. Generally, patients received a
total mesorectal excision (TME) for all cancers located
between 0 and 12 cm [20,21] and a partial mesorectal
excision (PME) for all cancers located higher than
12 cm. All anastomoses were performed by double
stapling technique.
After identifying all patients with a rectal adenocar-
cinoma, we eliminated all patients receiving a short
term radiation (5x5 Gy), conventional neoadjuvant ra-
diochemotherapy and all patients having complications
during the intensified neoadjuvant treatment or having
another malignancy in their history. Thereafter, we
stratified all remaining patients who received an inten-
sified neoadjuvant RCT as the “study group”, whereas
patients without any neoadjuvant treatment before
surgery represented the “control group”. There were
106 patients eligible to the study group, another 106
patients of the control group were matched in decreas-
ing preference by UICC stage, R-Status, tumor height,
T-, N-, V-, L-, M- and G-category of the TNM-system.
Tumor stage (TNM/UICC) was based exclusively on
histopathology of the surgical specimen and operative
findings. All patients with non-resected residual meta-
static disease (hepatic and/or pulmonary metastases)
were classified as R2-resections.
Histopathological work-up generally included a state-
ment of tumor response to the neoadjuvant radioche-
motherapy protocol for all neoadjuvant treated patients.
Regression was divided into four categories: no response –
only vital tumor was seen; poor to moderate regression –
large vital tumor complexes were seen in the majority of
the blocks. Good regression – better than category poor
to moderate response but not a complete response;
complete response – no residual tumor was found. Fur-
ther pathological subclassification in low- moderate –

















yT0 4.2 8.5 0
(y) T1 7.5 5.7 9.8
(y)T2 28.8 27.4 30.2
(y)T3 53.3 54.7 51.9






17.2 15.3 19.1 <0.001
(y)N0 51.4 52.8 50.0
(y)N1 25.9 27.4 24.5
(y)N2 22.6 19.8 25.5
UICC stage 0.31
UICC 0 1.9 3.8 0
UICC I 27.4 24.5 30.2
UICC II 16.0 17.0 15.1
UICC III 31.1 31.1 31.1




R0 76.8 79.0 74.5
R1 5.2 5.7 4.7
R2 18.0 15.2 20.8
V-Category <0.01
V0 71.1 81.0 61.3
V1 23.7 15.2 32.1
V2 5.2 3.8 6.6
L-Category 0.08
L0 80.3 85.4 75.2
L1 19.7 14.6 24.8
M-Category 1.00
M0 77.4 77.4 77.4
M1 22.6 22.6 22.6
G-Category 0.15
G1 11.4 15.2 7.5
G2 72.0 66.7 77.4
G3 16.6 18.1 15.1




























Upper Rectum 4.8 3.8 5.7
Middle Rectum 41.9 40.4 43.4
Lower Rectum 53.3 55.8 50.9
Tumorheight
(cm)
5.6 5.3 5.9 0.22
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not routinely performed.
Adjuvant treatment generally consists of a combination
of a continuous infusion 5-FU (1000 mg/m2 per day) and
a local radiation five days a week with a single dose of
1.8 Gy and a 5.4 Gy boost adding up to 55.8 Gy. After
completion of radiation, a chemotherapy analog to the
postoperative chemotherapy of the study group was
administrated.
Follow-up information was obtained from all patients of
the study and control group in 2011. The mean interval
between oncologic resection and follow-up was 4.3 ±
2.55 years in the study group and 3.8 ± 3.05 years in the
control group. On the basis of a standardized question-
naire primary end-points were analyzed and included local
recurrence, distant metastases, overall survival and cancer
related survival. Follow-up examinations were carried out
in cooperation with the referring physicians according to
the German S3 guidelines for colorectal cancer [4] and
provided a comprehensive and complete data collection.
The study was approved by the Medical Ethical
Committee of Rostock University.
Statistical analysis
Statistical analysis was performed using Statistical Package
for Social Science (SPSS) version 15.0. Statistical analysis
Table 3 Actuarial and estimated cancer-related outcome






















All UICC stages 69.8 67.9 71.7 0.65
UICC stage 0-III 86.4 82.7 90.1 0.25
Disease free
survival
UICC stage 0-III 76.5 70.4 82.7 0.09
Local recurrence
All UICC stages 5.2 5.7 4.7 1.00





All UICC stages 67.3 66.7 67.9 0.88
UICC stage 0-III 85.8 82.0 89.6 0.32
Disease free
survival
UICC stage 0-III 73.3 66.7 79.9 0.22
Local recurrence
All UICC stages 8.4 9.0 7.8 0.98
UICC stage 0-III 8.5 9.2 7.9 0.95
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test). Survival curves were calculated according to the
Kaplan-Meier method. Survival curves were tested for
significant differences using the log-rank test. A p value
of < 0.05 was considered as statistically significant.
Results
106 patients receiving an intensified neoadjuvant RCT
(treatment group) were matched with 106 patients, who
did not receive any neoadjuvant treatment (control group),
on the base of histopathological findings, for UICC stage,
R-Status, tumor height, T-, N-, V-, L-, M- and G-category
of the TNM-system.
Histopathology revealed any kind of local tumor regres-
sion in 92.5% of patients after intensified neoadjuvant
radiochemotherapy. In this patients’ subset, a poor to
moderate response was found in 45.3%, a good response
39.5% and a complete response in 7.5% (ypT0N0). At a
minimum, downstaging was achieved in about 30% of all
cases (Table 1: UICC-stage 0 and I).
Tables 1 and 2 show the results of the matching.
Matching was well balanced for UICC, presence of posi-
tive lymph nodes, R-status, presence of distant metastases
and tumor localization between the two groups. In con-
trast, significant differences were observed concerning a
less advanced T-stage (p = 0.02), a lower number of lymph
nodes examined (p < 0.001), a lower percentage of vascular
invasion (p < 0.01), and a lower comorbidity in the
study group. Nine patients (8.5%) revealed a complete
local response corresponding by ypT0. In UICC stage
0-III patients, one patient of each group had a local R2
resection, 5 patients of the treatment group and seven


















1 : 1.94 1 : 2.92 1 : 1.35 <0.01
Age (mean) 65.4 62.3 68.5 0.06
Comorbidity 77.0 68.6 85.5 <0.01
Pulmonary 9.1 5.7 12.5 0.01
Cardiovascular 23.9 21.9 26.0 0.52
Renal 7.2 6.7 7.7 0.80
Diabetes 19.1 11.4 26.9 <0.01
Hypertension 47.8 40.0 55.8 0.03
Others 48.9 39.0 58.7 <0.01
ASA score
(mean)
2.4 2.3 2.5 0.05Table 3 shows the actuarial and estimated 5-year sur-
vival data showing no significant differences. Figure 1
shows the overall estimated cancer related survival,
Figure 2 the estimated disease free survival and Figure 3
the local recurrence rates in the study and control
group in all patients without showing any differences
between groups. If only patients with UICC stage 0-III
(Figure 4) versus UICC stage IV (Figure 5) and UICC
stage 0-I (Figure 6) are separately analyzed, cancer re-
lated and disease free survival are not different be-
tween the two groups as well. In subgroup analysis, R0
resected, N1 and/or N2 positive patients showed no
significant differences in cancer related survival. In be-
have of low patient numbers, these figures are not
shown. However, UICC-stage dependent survival bene-
fits of the UICC 0-III (Figure 4) versus UICC stage IV
(Figure 5) become apparent.
Figure 1 This figure shows no difference in cancer related survival UICC stage 0 to IV depending on administrating intensified
neoadjuvant radiochemotherapy (p = 0.88) based on the matched pair analysis described in the text.
Schiffmann et al. BMC Cancer 2013, 13:388 Page 5 of 9
http://www.biomedcentral.com/1471-2407/13/388Discussion
In our study we retrospectively analyzed the long term
results of patients with rectal cancer subjected to inten-
sified neoadjuvant RCT compared with patients receiv-
ing no neoadjuvant treatment. In the absence of reliable
long-term outcome data of intensified treatment proto-
cols we report for the first time on cancer-related and
disease-free survival as well as local recurrence after anFigure 2 This figure shows no difference in disease free survival UICC
neoadjuvant radiochemotherapy (p = 0.22) based on the matched paoverall observation period of about 4 years after onco-
logic resection.
The main finding of our study is that intensified
neoadjuvant RCT resulted in a high tumor regression and
that patients’ long term prognosis after intensified RCT
matches prognosis of patients with the same postoperative
histopathological staging without neoadjuvant RCT. In
consequence, prognosis correlates with downstaging;stage 0 to III depending on administrating intensified
ir analysis described in the text.
Figure 3 This figure shows no difference for local recurrence depending on administrating intensified neoadjuvant radiochemotherapy
(p = 0.98) based on the matched pair analysis described in the text.
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downstaging is as good as the prognosis of a pT1N0M0
patient. Since our patient cohort was recruited over an ob-
servation period of 10 years with considerable changes in
pretherapeutic diagnostic staging approaches, meaningful
evaluation of downstaging was not possible, which is one
of the drawbacks of our study. However, in a previous re-
port, we tried to evaluate the effect of the intensifiedFigure 4 This figure shows no difference in cancer related survival UI
neoadjuvant radiochemotherapy (p = 0.32) based on the matched paneoadjuvant treatment regimen by histology on the basis
of tumor fibrosis [5].
The tumor regression and complete remission are
prognostic factors for overall survival [22,23]. The new
German Rectal Cancer Trial show a higher rate of
complete remission without a significantly higher rate of
toxicity by integrating a second drug in the neoadjuvant
radiochemotherapy schedule [24].CC stage 0 to III depending on administrating intensified
ir analysis described in the text.
Figure 5 This figure shows no difference in cancer related survival UICC stage IV depending on administrating intensified neoadjuvant
radiochemotherapy (p = 0.11) based on the matched pair analysis described in the text.
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category. Looking at patients with UICC-stage II and
III, without neoadjuvant therapy, the survival data differ
significantly. If, by the way of neoadjuvant therapy a
downstaging from a cN + category to a ypN0-category
has been reached, and the prognosis is as good as in
patients with a primary pN0-category, it would be anFigure 6 This figure shows no difference in disease free survival UICC
radiochemotherapy (p = 0.27) based on the matched pair analysis desexcellent result for intensified neoadjuvant radiochemo-
therapy. But this is exactly, what our matched pair analysis
shows. In terms of local control and survival there are no
statistically significant differences in the reached ypTNM-
category or in the primary pTNM-category.
One critical point in neoadjuvant treatment is the risk of
overstaging in the preoperative situation. In the multicenterstage 0-I depending on administrating intensified neoadjuvant
cribed in the text.
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is also a risk of understaging. A degree of uncertainty
despite better diagnostics must be accepted.
In the present analysis we matched also according
to the resection status, knowing that neoadjuvant
radiochemotherapy reduces the risk of incomplete resec-
tion and also knowing, complete resection is an important
prognostic factor for local control and survival. This is
perhaps one of the reasons that we see no benefit from
neoadjuvant radiochemotherapy in local control, as seen
in a couple of randomized trials like the German Rectal
Cancer Trial or the MRC-Trial before [1,25]. In our con-
trol group the rate of local recurrence of 5.2% after an
average follow-up of 4 years is rather low compared to
other authors describing 13% after 5 years [1,26]. This
may be attributed to a high surgical quality standard in
performing TME in our department, and a high standard
of radiooncological quality by a consequent postoperative
radiochemotherapy if necessary, with a high density of the
radiation dose, which is also a prognostic factor for local
control [27].
The cancer related survival in UICC stage 0-III is 82.7%
in the study group in comparison with 76% in the
neoadjuvant treatment arm of the German Rectal Cancer
Trial [1].
Comparable results to our findings in rectal cancer
can be observed in the neoadjuvant therapy of other
gastrointestinal tumors. Patients with primarily inoper-
able or borderline resectable tumors and an UICC stage
III category, receiving neoadjuvant radiochemotherapy,
following complete resection, have the same prognosis
as patients with a primarily resectable tumor situation
and an UICC stage I/II [28]. Other examples are adeno-
carcinoma of the esophagus and the esophagogastric
junction. The POET –Trial [29] shows a survival benefit
for patients with an ypN0 category in comparison with
an ypN + category.
Up to now, there are four randomized trials in rectal
cancer, comparing neoadjuvant radiochemotherapy to
intensified neoadjuvant radiochemotherapy. The follow up
period is too short for long-term results in local control
and survival.
Conclusions
Therefore our matched pair analysis is one of the first
steps to suggest, that intensified neoadjuvant radiochemo-
therapy improves survival in patients with rectal cancer by
downstaging to a better tumor situation.
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